HomeMarket NewsSmall CapsINVO Bioscience Reports Narrower Q3 Loss, Shares Surge Over 31% in Pre-Market...

INVO Bioscience Reports Narrower Q3 Loss, Shares Surge Over 31% in Pre-Market Trading

Actionable Trade Ideas

always free

image32 0

INVO Bioscience, Inc. (NASDAQ: INVO) witnessed a significant surge in pre-market trading following the companyโ€™s announcement of a narrower loss for the third quarter. The company posted a quarterly loss of 70 cents per share, a considerable improvement from the year-ago loss of $4.19 per share. Moreover, INVO Bioscience reported a staggering 314% year-over-year increase in quarterly sales, reaching $974,894.

This positive financial performance resulted in a remarkable 31.1% surge in INVO Bioscience shares, reaching $2.11 in pre-market trading.

Gainers in Pre-Market Trading

  • Alaunos Therapeutics, Inc. (NASDAQ: TCRT) observed a 62.9% increase in its pre-market trading value, reaching $0.1354, following a 12% dip on Monday.
  • reAlpha Tech Corp. (NASDAQ: AIRE) soared by 57.8% to $9.30 in pre-market trading after experiencing a 34% increase on Monday.
  • Hanryu Holdings, Inc. (NASDAQ: HRYU) witnessed a 40.2% rise to $1.36 in pre-market trading, rebounding from a 3% decline on Monday.
  • Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) displayed a 24.3% surge to $2.66 in pre-market trading subsequent to the companyโ€™s announcement of exploring strategic alternatives.
  • RedHill Biopharma Ltd. (NASDAQ: RDHL) ascended by 15.3% to $0.3574 in pre-market trading.
  • Absci Corporation (NASDAQ: ABSI) appreciated by 14.4% to $1.43 in pre-market trading after Almirall and Absci revealed an AI drug discovery partnership focused on rapidly developing novel dermatological disease treatments.
  • PaxMedica, Inc. (NASDAQ: PXMD) gained 12.3% to $1.92 in pre-market trading following the companyโ€™s research findings in the Annals of General Psychiatry regarding low-dose suramin intravenous infusions as a potential treatment for Autism Spectrum Disorder.
  • Advent Technologies Holdings, Inc. (NASDAQ: ADN) observed an 11.8% rise to $0.4848 in pre-market trading.
  • Singular Genomics Systems, Inc. (NASDAQ: OMIC) recorded an 11.4% increase to $0.39 in pre-market trading. The company is expected to release its financial results for the third quarter of 2023 after the closing bell on Nov. 14, 2023.

Losers in Pre-Market Trading

  • The Beauty Health Company (NASDAQ: SKIN) registered a 51.7% decline to $1.88 in pre-market trading following weaker-than-expected financial results for its third quarter and a revised net sales outlook. Additionally, the company suspended its long-term full-year 2025 forecast.
  • Harrow, Inc. (NASDAQ: HROW) plunged by 24.6% to $9.67 in pre-market trading as a result of reporting downbeat third-quarter financial results and lowering its revenue guidance.
  • Applied UV, Inc. (NASDAQ: AUVI) tumbled by 22.6% to $0.2090 in pre-market trading after disclosing selected preliminary financial results for the third quarter.
  • Akili, Inc. (NASDAQ: AKLI) experienced a 21.4% decline to $0.3531 in pre-market trading, despite posting a narrower-than-expected quarterly loss.
  • HeartCore Enterprises, Inc. (NASDAQ: HTCR) dropped by 16.3% to $0.4350 in pre-market trading after reporting downbeat third-quarter sales.
  • Peraso Inc. (NASDAQ: PRSO) fell by 14.7% to $0.2038 in pre-market trading subsequent to the companyโ€™s announcement of third-quarter results.
  • Fisker Inc. (NYSE: FSR) declined by 13.4% to $3.56 in pre-market trading following the release of its third-quarter results.
  • TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) saw a 13.1% decrease to $0.1859 in pre-market trading after posting a profit for the third quarter, despite declining around 7% on Monday.
  • Tenax Therapeutics, Inc. (NASDAQ: TENX) decreased by 10.9% to $0.5527 in pre-market trading. The decline follows a 297% surge on Monday morning after the FDA cleared the IND for TNX-103, an oral levosimendan, to treat pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF).
  • Beyond Air, Inc. (NASDAQ: XAIR) experienced a 10.3% descent to $1.82 in pre-market trading following weak quarterly results.

For more financial insights, check out: Home Depot Likely To Report Lower Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call


Complete Humain, Sentiment 10

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.